Pfizer has announced that the second and third phase trials have begun on the new COVID-19 drug it is developing. new drug; It aims to stop an enzyme that allows the virus to multiply.
While the best current option in the fight against the coronavirus epidemic is vaccines, a new announcement from Pfizer was shared today. Company, COVID-19 announced that the second and third phase trials of a new drug planned to be used in the treatment of
PfizerAccording to the statement made by the drug under development; if successful will stop the virus before it has a chance to reproduce and prevent the development of symptoms.
Trials will be conducted on 2,660 adults:
In the announcement it shared, Pfizer stated that the trial was carried out with people who have previously had COVID-19 and have shown symptoms, sharing the same house. 2,660 healthy adult individuals over the age of 18 stated that it will be implemented.
The drug is aimed at stopping an enzyme that allows the virus to multiply:
Head of Global Research, Development and Medicine at Pfizer Michael Dolsten, on the subject “We believe that in the fight against Covid-19, which continues to affect the world, it is necessary to develop effective treatments for people who are infected or exposed to the virus, as well as vaccines that control the infection.” used the phrases.
A virus that causes the COVID-19 virus to multiply stop the production of the enzyme new drug aimed at; HIV It was stated that it will be used together with ritonavir, a drug that is widely used in infections.
Before Pfizer, it was announced that Merck, a US pharmaceutical company, and Swedish Rocde, were also in the process of developing pill-form drugs to prevent and treat COVID-19 infections.
Source :
https://www.ntv.com.tr/saglik/pfizer-covid-19-ilacinin-denemelere-basladigini-acikladi,6yriaEnTuU6WAq5GQUxDCw